VIDEO: Venetoclax plus conditioning chemotherapy appears safe before HCT in high-risk AML, MDS
Researchers reported no association between adding venetoclax to fludarabine and busulfan conditioning chemotherapy for allogeneic hematopoietic cell transplantation and increased toxicity in patients with high-risk myeloid malignancies.
Presenting at the ASH Annual Meeting and Exposition, Jacqueline S. Garcia, MD, of the department of medical oncology, Dana-Farber Cancer Institute, reported phase 1 data on whether the transplant approach could be optimized without causing more toxicity in patients with high-risk acute myeloid leukemia, myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
“Overall, we’re encouraged that venetoclax could be added to conditioning chemotherapy ... survival so far has been encouraging,” Garcia said in a video interview. “This was not a randomized study, but this was a very high-risk and sick population. Because the relapse is stull occurring, we amended the study to have a separate arm to assess [venetoclax]plus conditioning, but now with a post-transplant maintenance therapy to further eliminate and reduce the risk of relapse.”
Collapse
Garcia JS, et al. Abstract 190. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.